Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($1.14), $0.22 better than the analyst estimate of ($1.36). Revenue for the quarter came in at $3.04 million versus the consensus estimate of $49.2 thousand.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.